Pharma BD Deal Intelligence
Gilead's $1.4B acquisition of CV Therapeutics landed as a partial win, built around Ranexa. The deal delivered solid financial return but weaker strategic fit, leaving the "Partially Achieved" verdict rather than a clean success.
Gilead / CV Therapeutics: Partially Achieved (Score: 64/100)
Full analysis, sources & comparables →Gilead acquired CV Therapeutics for $1.4B for Ranexa and Lexiscan.
Gilead / CV Therapeutics: Partially Achieved (Score: 64/100)
Assessment window: 10yr post-close.
6M US cases/yr · $2.0B US Angina Therapeutics Market (2009) · 15.4M Americans with CHD
Chronic stable angina affects over 6 million Americans. Ranexa (ranolazine) was the first new angina drug in over a decade (2006), working via late sodium current inhibition. Gilead's $1.4B acquisition of CV Therapeutics added cardiovascular assets.
Ranexa achieved ~$600M peak US sales but became non-core as Gilead pivoted to HCV (Sovaldi/Harvoni) and HIV. Ranexa went generic after 2019 patent expiry. The deal is viewed as strategically secondary to the Pharmasset acquisition.
Gilead Sciences Inc. closes acquisition/merger of CV Therapeutics Inc. for $1.4B, establishing strategic position and initiating integration.
Strategic Fit: 55/100 | Financial Return: 72/100 | Pipeline Outcome: 65/100 | Integration: 70/100 | Deal Difficulty: 40/100. Partially Achieved overall outcome.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / CV Therapeutics Inc. (this deal) | 2009 | $1.4B | 62 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2009 deals · Gilead Sciences Inc. deals · Cardiovascular deals